In May 2026, a short case report did something unusual for a medical journal article: it went viral. An 80-year-old woman with advanced Alzheimer's, after a decade of decline, was given psilocybin-containing mushrooms. Within a day, her family reported, she began speaking about her life again, in full sentences (Frontiers in Neuroscience).
If you love someone with dementia, a story like that can land like a lightning bolt. So let's look at it carefully: what it shows, what it doesn't, and what serious research is actually testing right now.
Why researchers are paying attention
There's a real scientific reason for interest, beyond hope:
Neuroplasticity. In lab and animal studies, classic psychedelics promote the growth of new connections between brain cells. Alzheimer's is, in part, a disease of lost connections.
The right receptors in the right places. Psychedelics act on serotonin 2A receptors, which are concentrated in brain regions hit hard by dementia, like the prefrontal cortex and hippocampus. These receptors decline as Alzheimer's progresses (Vann Jones and O'Kelly, 2020).
Inflammation. Some psychedelics show anti-inflammatory effects in lab research, and chronic brain inflammation is increasingly seen as part of the Alzheimer's story.
Mood. Depression is common after a dementia diagnosis, and research suggests people with more pronounced depression tend to decline faster. Psilocybin has strong early evidence for depression in other populations.
As one recent overview put it, lab and animal studies suggest psychedelics may affect nerve-cell growth, inflammation and brain networks, but whether that happens in people with Alzheimer's is still unknown (The Conversation).
What that viral case actually showed
The woman's improvements were real enough to document, but they were temporary. The authors were explicit that this does not mean the disease was reversed. Their more modest suggestion: some abilities thought to be permanently lost in late-stage dementia may not be fully gone, only inaccessible, and might briefly come back under certain conditions.
It was one person, with no standardized cognitive testing before and after, no brain imaging, and no comparison. It's a reason to ask questions, not an answer.
What's being studied now
Johns Hopkins: a small pilot study of psilocybin for depression in people with mild cognitive impairment or early Alzheimer's, combining two psilocybin sessions with psychological support. It's focused on mood and quality of life, not reversing memory loss, and results haven't been published yet (Johns Hopkins).
UC Berkeley: the PLASTICITY study, launched in 2026, is the first psychedelic brain-imaging study focused specifically on healthy older adults, testing whether findings from animal research translate to aging humans (Berkeley News).
UCSF: a placebo-controlled trial that began in June 2026 is giving psilocybin to adults 50 to 85 with low well-being and looking at how biomarkers for early, pre-symptom Alzheimer's shape the effects (UCSF).
Low-dose LSD: an earlier trial in 48 healthy adults averaging 63 years old found repeated very low doses were safe and well tolerated, with no impairment in cognition or balance, and was designed as a first step toward Alzheimer's research (Psychopharmacology, 2019).
What the research does not show, yet
It's worth saying plainly:
There is no published human evidence that psychedelics slow, stop or reverse Alzheimer's or any dementia.
No controlled trial in people with dementia has reported results. The most dementia-specific study, at Johns Hopkins, is small and focused on depression.
Lab and animal findings often don't hold up in people. The Alzheimer's drug field is full of compounds that looked promising in mice and failed in humans.
What the research does point to is a few genuinely open questions worth funding: can psychedelics ease depression and distress after a diagnosis? Can they support healthy brain aging? Could they help people with dementia, and their families, find moments of connection and meaning? Those questions are now finally being studied.
Risks for older adults and people with dementia
Older adults were excluded from most psychedelic research until recently, so there's much less safety data. Some real concerns:
Heart and blood pressure. Psychedelics can raise both, and older adults are more likely to have heart conditions.
Medications. Many older adults take several. Some interact dangerously; for example, lithium combined with psychedelics has been linked to seizures. Others can blunt or intensify effects.
Confusion and falls. An altered state can be disorienting for anyone, and more so for someone with cognitive impairment. Falls and frightening confusion are real risks.
Psychological distress. A person with dementia may be less able to understand, describe or recover from a difficult experience.
Consent. This is the one I want families to think hardest about. As dementia progresses, a person's ability to understand and agree to an intense experience changes. Giving someone a psychedelic they can't meaningfully consent to raises serious ethical and legal problems, however loving the intention.
Legal status. Outside of research and a few state programs, psilocybin and LSD remain illegal.
If you're a family member or caregiver
If a story like the viral case has you wondering about your parent or partner, that's completely understandable. A few suggestions:
Talk to their neurologist or geriatric psychiatrist, and ask about current research opportunities.
Look into clinical trials. They offer screening, medical oversight and support that no informal setting can. Search ClinicalTrials.gov or contact academic memory centers directly.
Don't attempt this at home with someone who has dementia. The risks and consent issues are too serious.
Take care of yourself, too. Caregiver grief, exhaustion and anticipatory loss are profound. Support for you matters on its own terms.
If you're older and curious for yourself
Many older adults without dementia are exploring psychedelics for meaning, grief, mortality and quality of life. If that's you, get a medical checkup first, review your medications with a doctor or pharmacist, and favor research settings or legal, supervised programs over informal ones.
Where I come in
I'm an integration coach, not a clinician, and I don't provide or source substances. I support people, including older adults and their families, in preparing for and making sense of psychedelic experiences, and in facing big questions about aging, memory, legacy and loss. If you're a caregiver carrying the weight of a loved one's decline, I'm also glad to simply talk it through.
Sessions are offered in person in NYC Area or online. Reach out through the contact form.
Sign up for our newsletter for occasional reflections, events, and offerings from Brooklyn Balance. No spam — just thoughtful updates.
This post is for education, not medical advice. If you or someone you care for is in crisis, call or text 988. For dementia support, the Alzheimer's Association 24/7 Helpline is 1-800-272-3900.
Josh Jupiter is a psychedelic integration coach and founder of Brooklyn Balance, a wellness practice in Brooklyn, New York. This article is for educational and informational purposes only and does not constitute medical or legal advice. For guidance on any of the therapeutic options discussed, please consult a qualified healthcare provider. For information on clinical trials, visit ClinicalTrials.gov.
Ready to go deeper? Reach out to Josh to learn about one-on-one integration coaching, group programs, and upcoming workshops at Brooklyn Balance.